Related Experiment Videos
Structural basis for Chk1 inhibition by UCN-01
Baoguang Zhao1, Michael J Bower, Patrick J McDevitt
1Department of Structural Biology, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA.
The Journal of Biological Chemistry
|September 24, 2002
Summary
The crystal structure reveals how UCN-01, a Chk1 inhibitor, binds to the Chk1 kinase domain. This provides insight into the DNA damage response and cell cycle control mechanisms.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Checkpoint kinase 1 (Chk1) is crucial for the DNA damage response and G(2)/M cell cycle control.
- UCN-01 (7-hydroxystaurosporine) is a potent Chk1 inhibitor currently in clinical trials, known to abrogate DNA damage-induced G(2)/M checkpoints.
Purpose of the Study:
- To elucidate the structural basis of Chk1 inhibition by UCN-01.
- To understand the molecular interactions responsible for UCN-01's potency and selectivity.
Main Methods:
- X-ray crystallography was employed to determine the crystal structure of the Chk1 kinase domain.
- Structures were solved for Chk1 in complex with UCN-01, staurosporine, and SB-218078.
Main Results:
- All three inhibitors (UCN-01, staurosporine, SB-218078) bind within the ATP-binding pocket of Chk1 with minimal conformational changes.
- The selectivity of UCN-01 for Chk1 over cyclin-dependent kinases is attributed to a hydroxyl group in its lactam moiety interacting with the ATP-binding pocket.
- Detailed hydrophobic and hydrogen-bonding interactions between UCN-01 and the Chk1 kinase domain were identified.
Conclusions:
- The determined crystal structures provide a detailed molecular understanding of Chk1 inhibition by UCN-01.
- The structural insights support the observed potency and selectivity of UCN-01 as a Chk1 inhibitor.
- This structural information can aid in the design of novel Chk1-targeting therapeutics for cancer treatment.